Rafarma Pharmaceuticals, Inc. (RAFA)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rafarma Pharmaceuticals, Inc. (RAFA) with AI Score 44/100 (Weak). Rafarma Pharmaceuticals, Inc. is a pharmaceutical company focused on the production and sale of generic antibiotics and specialty pharmaceuticals in Russia. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Rafarma Pharmaceuticals, Inc. (RAFA) Healthcare & Pipeline Overview
Rafarma Pharmaceuticals, Inc. produces and distributes generic antibiotics and specialty pharmaceuticals in Russia, including cephalosporin-based and anti-cancer drugs. Operating as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd., it navigates the competitive landscape of the Russian pharmaceutical market with a focus on various drug formulations.
Investment Thesis
Rafarma Pharmaceuticals, Inc. presents a focused investment opportunity within the Russian pharmaceutical market, specializing in generic antibiotics and specialty drugs. With a market capitalization of $0.01 billion and a P/E ratio of 19.50, the company demonstrates potential for growth, supported by a gross margin of 7.3% and a profit margin of 3.2%. Key growth catalysts include the collaboration with PlantEXT Ltd. to develop medical cannabis suppositories and the expansion of its product offerings in the Russian market. However, investors may want to evaluate the risks associated with operating in the OTC market and the competitive pressures within the pharmaceutical industry. The company's beta of 0.54 suggests lower volatility compared to the market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion indicates a micro-cap company with potential for high growth but also higher risk.
- P/E ratio of 19.50 suggests the company is trading at a moderate valuation compared to its earnings.
- Gross margin of 7.3% reflects the company's profitability after accounting for the cost of goods sold.
- Profit margin of 3.2% indicates the percentage of revenue that turns into profit after all expenses, including taxes, are paid.
- Beta of 0.54 suggests the stock is less volatile than the overall market.
Competitors & Peers
Strengths
- Established manufacturing facility in Russia.
- Focus on generic antibiotics and specialty pharmaceuticals.
- Collaboration with PlantEXT Ltd. for innovative products.
- Diverse product portfolio addressing various medical needs.
Weaknesses
- Small market capitalization.
- Low gross and profit margins.
- Reliance on the Russian market.
- OTC market listing.
Catalysts
- Ongoing: Expansion of product portfolio with new generic drugs and specialty pharmaceuticals.
- Ongoing: Collaboration with PlantEXT Ltd. to develop and commercialize medical cannabis suppositories.
- Ongoing: Geographic expansion within Russia to reach a wider customer base.
- Upcoming: Potential strategic acquisitions and partnerships to expand market presence (Timeline: 2027).
- Upcoming: Exploration of export opportunities to diversify revenue streams (Timeline: 2027-2028).
Risks
- Ongoing: Intense competition from domestic and international pharmaceutical companies.
- Potential: Regulatory changes in the Russian pharmaceutical market affecting pricing and market access.
- Potential: Economic instability in Russia impacting demand for pharmaceutical products.
- Potential: Fluctuations in currency exchange rates affecting profitability.
- Ongoing: Risks associated with operating on the OTC Other tier, including limited liquidity and transparency.
Growth Opportunities
- Expansion of Product Portfolio: Rafarma can expand its product portfolio by introducing new generic drugs and specialty pharmaceuticals to address unmet medical needs in the Russian market. This includes investing in research and development to create innovative formulations and dosages. The market for generic drugs is expected to grow as patents for branded drugs expire, providing a significant opportunity for Rafarma to increase its revenue and market share. Timeline: Ongoing.
- Collaboration with PlantEXT Ltd.: The collaboration with PlantEXT Ltd. to research and manufacture medical cannabis suppositories for patients suffering from inflammatory bowel disease presents a unique growth opportunity. The market for medical cannabis is expanding globally, and Rafarma can leverage this partnership to enter a new and potentially lucrative market segment. Successful development and commercialization of these suppositories could significantly boost the company's revenue and brand recognition. Timeline: Ongoing.
- Geographic Expansion within Russia: Rafarma can expand its geographic reach within Russia by establishing new distribution channels and partnerships with local pharmacies and healthcare providers. This will allow the company to reach a wider customer base and increase its sales volume. The Russian pharmaceutical market is vast and diverse, with significant regional variations in demand and healthcare infrastructure. Timeline: Ongoing.
- Strategic Acquisitions and Partnerships: Rafarma can pursue strategic acquisitions and partnerships with other pharmaceutical companies to expand its product portfolio, access new technologies, and enter new markets. This includes acquiring companies with complementary product lines or technologies, as well as forming partnerships with research institutions and universities to develop new drugs and therapies. Timeline: Ongoing.
- Focus on Export Markets: Rafarma can explore opportunities to export its products to other countries in the region, particularly those with similar healthcare needs and regulatory environments. This will allow the company to diversify its revenue streams and reduce its reliance on the Russian market. The export market for generic drugs is growing rapidly, driven by increasing demand for affordable healthcare solutions in developing countries. Timeline: 2027-2028.
Opportunities
- Expansion of product portfolio with new generic drugs.
- Geographic expansion within Russia.
- Strategic acquisitions and partnerships.
- Growth in the medical cannabis market.
Threats
- Intense competition from domestic and international players.
- Regulatory changes in the Russian pharmaceutical market.
- Economic instability in Russia.
- Fluctuations in currency exchange rates.
Competitive Advantages
- Established manufacturing and distribution facility in Russia.
- Collaboration with PlantEXT Ltd. for medical cannabis suppositories.
- Focus on generic antibiotics and specialty pharmaceuticals.
- Product portfolio addressing various medical needs.
About RAFA
Rafarma Pharmaceuticals, Inc., originally named Johnston Acquisition Corp. before its renaming in October 2012, is a multi-product pharmaceutical company specializing in the production and sale of drugs, generic antibiotics, and specialty pharmaceuticals within the Russian market. The company's product portfolio includes cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs, available in various forms such as injections, ampulla packaged products, child suspensions, tablets, and capsules. Additionally, Rafarma offers medications for accidental wounds, inflammatory eye diseases, and immunological disorders. Based in Sandy, Utah, Rafarma maintains a manufacturing and distribution facility in Russia, allowing it to serve the local market effectively. A significant collaboration with PlantEXT Ltd. is underway to research and manufacture medical cannabis suppositories targeting patients with inflammatory bowel disease, showcasing the company's innovation efforts. Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd. since October 19, 2020. The company focuses on providing a range of pharmaceutical products to address various medical needs in the Russian healthcare sector.
What They Do
- Produces and sells generic antibiotics in Russia.
- Offers specialty pharmaceuticals for various medical conditions.
- Manufactures cephalosporin-based products.
- Develops anti-cancer drugs in different formulations.
- Provides drugs for accidental wounds and inflammatory eye diseases.
- Researches and manufactures medical cannabis suppositories through a collaboration with PlantEXT Ltd.
Business Model
- Develops and manufactures generic and specialty pharmaceutical products.
- Sells products through distribution channels in Russia.
- Generates revenue from the sale of pharmaceutical products.
- Collaborates with other companies for research and development.
Industry Context
Rafarma Pharmaceuticals, Inc. operates within the Drug Manufacturers - Specialty & Generic industry, which is characterized by intense competition and regulatory scrutiny. The Russian pharmaceutical market, where Rafarma primarily operates, is influenced by government policies, pricing regulations, and local demand for affordable medications. The company's focus on generic antibiotics and specialty drugs positions it to capitalize on the growing demand for cost-effective healthcare solutions. However, it faces competition from both domestic and international players, including BIOE, IGPK, LMLLF, LVVV, and NRPR, requiring continuous innovation and strategic partnerships to maintain market share.
Key Customers
- Hospitals and clinics in Russia.
- Pharmacies and drugstores.
- Patients requiring generic antibiotics and specialty pharmaceuticals.
- Healthcare providers prescribing medications.
Financials
Chart & Info
Rafarma Pharmaceuticals, Inc. (RAFA) stock price: Price data unavailable
Latest News
No recent news available for RAFA.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RAFA.
Price Targets
Wall Street price target analysis for RAFA.
MoonshotScore
What does this score mean?
The MoonshotScore rates RAFA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Sergey Brusnitsin
CEO
Sergey Brusnitsin serves as the CEO of Rafarma Pharmaceuticals, Inc. While detailed background information is limited, his leadership is crucial for guiding the company's strategic direction and operational execution in the Russian pharmaceutical market. His expertise in pharmaceutical management and market dynamics is essential for navigating the competitive landscape and regulatory environment. Further details on his education and prior experience are not available.
Track Record: Specific achievements and milestones under Sergey Brusnitsin's leadership are not detailed in the provided information. However, as CEO, he is responsible for overseeing the company's operations, driving growth, and ensuring the successful development and commercialization of pharmaceutical products. His tenure involves navigating the challenges and opportunities within the Russian healthcare sector.
RAFA OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Rafarma Pharmaceuticals, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and liquidity, and may not be required to provide regular financial disclosures. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Lack of regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags or warning signs, such as lawsuits or investigations.
- Determine the company's ownership structure and potential conflicts of interest.
- Consult with a financial advisor or legal professional.
- Established manufacturing facility in Russia.
- Focus on generic antibiotics and specialty pharmaceuticals.
- Collaboration with PlantEXT Ltd. for innovative products.
- Company has been in operation since 2012.
- Operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
RAFA Healthcare Stock FAQ
What does Rafarma Pharmaceuticals, Inc. do?
Rafarma Pharmaceuticals, Inc. is a pharmaceutical company that develops, manufactures, and sells generic antibiotics and specialty pharmaceuticals in Russia. The company's product portfolio includes cephalosporin-based products, anti-cancer drugs, and medications for various medical conditions. Rafarma operates a manufacturing and distribution facility in Russia and collaborates with PlantEXT Ltd. to research and manufacture medical cannabis suppositories. The company focuses on providing affordable and accessible healthcare solutions to the Russian market.
What do analysts say about RAFA stock?
As of 2026-03-17, there is no available analyst coverage for Rafarma Pharmaceuticals, Inc. due to its OTC listing and small market capitalization. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks. Key valuation metrics include a P/E ratio of 19.50, a gross margin of 7.3%, and a profit margin of 3.2%. Growth considerations include the company's expansion plans, collaboration with PlantEXT Ltd., and potential strategic acquisitions.
What are the main risks for RAFA?
The main risks for Rafarma Pharmaceuticals, Inc. include intense competition from domestic and international pharmaceutical companies, regulatory changes in the Russian pharmaceutical market, economic instability in Russia, and fluctuations in currency exchange rates. Additionally, the company faces risks associated with operating on the OTC Other tier, including limited liquidity, transparency, and regulatory oversight. Investors should carefully consider these risks before investing in RAFA.
What are the key factors to evaluate for RAFA?
Rafarma Pharmaceuticals, Inc. (RAFA) currently holds an AI score of 44/100, indicating low score. Key strength: Established manufacturing facility in Russia.. Primary risk to monitor: Ongoing: Intense competition from domestic and international pharmaceutical companies.. This is not financial advice.
How frequently does RAFA data refresh on this page?
RAFA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven RAFA's recent stock price performance?
Recent price movement in Rafarma Pharmaceuticals, Inc. (RAFA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established manufacturing facility in Russia.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider RAFA overvalued or undervalued right now?
Determining whether Rafarma Pharmaceuticals, Inc. (RAFA) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying RAFA?
Before investing in Rafarma Pharmaceuticals, Inc. (RAFA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC listing and limited public disclosures.
- AI analysis pending for RAFA.